down arrow

Acumen Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00509G2093
USD
2.15
0.03 (1.42%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.112.28

52 Week

0.862.46
Valuation
Technical
Day's Volume

CASH

264.04 k

Shareholding (Jun 2025)

FII

4.96%

Held by 39 FIIs

DII

73.36%

Held by 18 DIIs

Promoter

8.40%

How big is Acumen Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Acumen Pharmaceuticals, Inc. has a market capitalization of 73.90 million and reported net sales of 0.00 million with a net profit of -116.26 million for the latest four quarters. As of Dec 24, the company's shareholder's funds were 181.82 million, and total assets amounted to 238.99 million.

As of Jun 18, Acumen Pharmaceuticals, Inc. has a market capitalization of 73.90 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -116.26 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds were 181.82 million, and total assets amounted to 238.99 million.

Read More

What does Acumen Pharmaceuticals, Inc. do?

22-Jun-2025

Acumen Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $29 million and a market cap of $73.90 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -75.93%.

Overview: <BR>Acumen Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -29 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 73.90 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -75.93% <BR>Price to Book: 0.48<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Acumen Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2021, Acumen Pharmaceuticals, Inc. is considered overvalued with a significant downgrade in its valuation outlook, reflected by a negative Return on Equity of -75.93% and poor performance compared to peers and the S&P 500.

As of 16 August 2021, Acumen Pharmaceuticals, Inc. has moved from a grade of risky to does not qualify, indicating a significant downgrade in its valuation outlook. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 0.47 and an EV to EBITDA ratio of 0.37, which suggest that the market is not accurately reflecting its financial health. The negative Return on Equity (ROE) of -75.93% further underscores the challenges the company faces.<BR><BR>In comparison to its peers, Acumen's valuation metrics are starkly unfavorable. For instance, Soleno Therapeutics, Inc. has a P/E ratio of -20.32, while Phibro Animal Health Corp. boasts a much more favorable P/E ratio of 21.68, highlighting the disparity in market perception. Additionally, Acumen's stock has underperformed significantly over the past year, with a return of -46.75% compared to the S&P 500's gain of 10.26%, reinforcing the notion that the stock is overvalued in the current market context.

Read More

Is Acumen Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Acumen Pharmaceuticals, Inc. shows a mildly bullish trend despite mixed signals from indicators, while underperforming the S&P 500 with year-to-date and one-year returns of -23.26% and -45.9%, respectively.

As of 12 September 2025, the technical trend for Acumen Pharmaceuticals, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD and moving averages indicate a mildly bullish stance, while the Bollinger Bands show a mixed signal with a bearish monthly outlook. The KST is bullish on a weekly basis, but the Dow Theory reflects a mildly bearish trend. Overall, the stock is currently in a mildly bullish position, but the strength is tempered by mixed signals from other indicators.<BR><BR>In terms of performance, Acumen has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -23.26% versus the S&P's 12.22%, and a one-year return of -45.9% compared to the S&P's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 85 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-117.32%

stock-summary
Price to Book

0.73

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
70.63%
0%
70.63%
6 Months
76.23%
0%
76.23%
1 Year
19.44%
0%
19.44%
2 Years
-32.81%
0%
-32.81%
3 Years
-61.4%
0%
-61.4%
4 Years
-68.75%
0%
-68.75%
5 Years
0%
0%
0.0%

Acumen Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-41.14%
EBIT Growth (5y)
-278.90%
EBIT to Interest (avg)
-31.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
88.22%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.47
EV to EBIT
0.37
EV to EBITDA
0.37
EV to Capital Employed
-1.30
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-75.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 18 Schemes (13.29%)

Foreign Institutions

Held by 39 Foreign Institutions (4.96%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs -76.72% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.70",
          "val2": "-24.30",
          "chgp": "-71.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.00",
          "val2": "-20.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -95.23% vs -22.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-113.80",
          "val2": "-61.00",
          "chgp": "-86.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "0.60",
          "chgp": "583.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.60",
          "val2": "-1.40",
          "chgp": "214.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-102.30",
          "val2": "-52.40",
          "chgp": "-95.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-41.70
-24.30
-71.60%
Interest
1.00
1.00
Exceptional Items
-0.00
1.10
-100.00%
Consolidate Net Profit
-41.00
-20.50
-100.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -100.00% vs -76.72% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-113.80
-61.00
-86.56%
Interest
4.10
0.60
583.33%
Exceptional Items
1.60
-1.40
214.29%
Consolidate Net Profit
-102.30
-52.40
-95.23%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -95.23% vs -22.14% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Acumen Pharmaceuticals, Inc. stock-summary
stock-summary
Acumen Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."